Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 10/20 | 0.72 |
| ▸ | MAOB | P27338 | 8/20 | 0.67 |
| ▸ | MAOA | P21397 | 4/20 | 0.67 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.67 |
| ▸ | SDHA | P31040 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | CALML3 | P27482 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6160243 | 1.00 | F10 (0.72) | F10MAOBMAOAPTGS1SDHA | |
| Eperezolid SCHEMBL186562 | 0.94 | MAOB (0.76) | F10MAOBMAOAPTGS1SDHA | |
| Eperezolid SCHEMBL1176950 | 0.94 | MAOB (0.76) | F10MAOBMAOAPTGS1SDHA | |
| Eperezolid SCHEMBL29421647 | 0.94 | MAOB (0.76) | F10MAOBMAOAPTGS1SDHA | |
| Eperezolid SCHEMBL5325217 | 0.93 | MAOB (0.75) | F10MAOBMAOAPTGS1SDHA | |
| SCHEMBL6158660 | 0.92 | F10 (0.71) | F10MAOBMAOAPTGS1SDHA | |
| SCHEMBL6158654 | 0.92 | F10 (0.71) | F10MAOBMAOAPTGS1SDHA | |
| SCHEMBL7161407 | 0.92 | F10 (0.69) | F10MAOBMAOAPTGS1SDHA | |
| SCHEMBL7161413 | 0.92 | F10 (0.69) | F10MAOBMAOAPTGS1SDHA | |
| SCHEMBL7709919 | 0.92 | MAOB (0.64) | F10MAOBMAOAPTGS1SDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0984947-B8 | OXAZOLIDINONE ANTIBACTERIAL AGENTS HAVING A THIOCARBONYL FUNCTIONALITY | PHARMACIA & UPJOHN CO LLC (US) | 2005-06-15 | — | — | EP | claimed |
| EP-0984947-B1 | OXAZOLIDINONE ANTIBACTERIAL AGENTS HAVING A THIOCARBONYL FUNCTIONALITY | UPJOHN CO (US) | 2005-04-20 | — | — | EP | claimed |
| US-6362189-B1 | GRAMNEGATIVE, GRAMPOSITIVE BACTERIA | PHARMACIA AND UPJOHN COMPANY | 2002-03-26 | — | — | US | claimed |
| US-20020016323-A1 | Oxazolidinone antibacterial agents having a thiocarbonyl functionality | PHARMACIA & UPJOHN COMPANY | 2002-02-07 | — | — | US | claimed |
| US-20010041728-A1 | Oxazolidinone antibacterial agents having a thiocarbonyl functionality | HESTER JACKSON B (US) | 2001-11-15 | — | — | US | claimed |
| EP-0984947-A1 | OXAZOLIDINONE ANTIBACTERIAL AGENTS HAVING A THIOCARBONYL FUNCTIONALITY | PHARMACIA & UPJOHN COMPANY (US) | 2000-03-15 | — | — | EP | claimed |
| WO-1998054161-A1 | OXAZOLIDINONE ANTIBACTERIAL AGENTS HAVING A THIOCARBONYL FUNCTIONALITY | PHARMACIA & UPJOHN COMPANY (US) | 1998-12-03 | — | — | WO | claimed |
| EP-0984947-B8 | OXAZOLIDINONE ANTIBACTERIAL AGENTS HAVING A THIOCARBONYL FUNCTIONALITY | PHARMACIA & UPJOHN CO LLC (US) | 2005-06-15 | — | — | EP | disclosed |
| EP-0984947-B1 | OXAZOLIDINONE ANTIBACTERIAL AGENTS HAVING A THIOCARBONYL FUNCTIONALITY | UPJOHN CO (US) | 2005-04-20 | — | — | EP | disclosed |
| EP-1451164-A2 | AMIDE DERIVATIVES HAVING IMPROVED SOLUBILITY | PHARMACIA & UPJOHN COMPANY (US) | 2004-09-01 | — | — | EP | disclosed |
| US-6537986-B2 | With thiourea, thioamide, or dithiocarbamate functionality; (S)-N-(((3-(3-fluoro-4-morpholinyl)phenyl)-2-oxo-5 -oxazolidinyl)methyl)thioacetamide for example; treats multiple-resistant staphylococci | PHARMACIA & UPJOHN COMPANY | 2003-03-25 | — | — | US | disclosed |
| WO-2003006440-A2 | AMIDE-CONTAINING COMPOUND HAVING IMPROVED SOLUBILITY AND METHOD OF IMPROVING THE SOLUBILITY OF AN AMIDE-CONTAINING COMPOUND | PHARMACIA & UPJOHN COMPANY (US) | 2003-01-23 | — | — | WO | disclosed |
| US-6362189-B1 | GRAMNEGATIVE, GRAMPOSITIVE BACTERIA | PHARMACIA AND UPJOHN COMPANY | 2002-03-26 | — | — | US | disclosed |
| EP-1133493-A1 | OXAZOLIDINONE ANTIBACTERIAL AGENTS HAVING A THIOCARBONYL FUNCTIONALITY | PHARMACIA & UPJOHN COMPANY (US) | 2001-09-19 | — | — | EP | disclosed |
| US-6255304-B1 | AIDS THERAPY | PHARMACIA & UPJOHN COMPANY | 2001-07-03 | — | — | US | disclosed |
| US-6218413-B1 | Oxazolidinone antibacterial agents having a thiocarbonyl functionality | PHARMACIA & UPJOHN COMPANY | 2001-04-17 | — | — | US | disclosed |
| WO-2000032599-A1 | OXAZOLIDINONE ANTIBACTERIAL AGENTS HAVING A THIOCARBONYL FUNCTIONALITY | PHARMACIA & UPJOHN COMPANY (US) | 2000-06-08 | — | — | WO | disclosed |
| EP-0984947-A1 | OXAZOLIDINONE ANTIBACTERIAL AGENTS HAVING A THIOCARBONYL FUNCTIONALITY | PHARMACIA & UPJOHN COMPANY (US) | 2000-03-15 | — | — | EP | disclosed |
| WO-1998054161-A9 | OXAZOLIDINONE ANTIBACTERIAL AGENTS HAVING A THIOCARBONYL FUNCTIONALITY | UPJOHN CO (US) | 1999-04-08 | — | — | WO | disclosed |
| WO-1998054161-A1 | OXAZOLIDINONE ANTIBACTERIAL AGENTS HAVING A THIOCARBONYL FUNCTIONALITY | PHARMACIA & UPJOHN COMPANY (US) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010041728-A1 | Oxazolidinone antibacterial agents having a thiocarbonyl functionality | OXA1L, MRPL21, TOP1 | F10 3383/4885MAOB 2998/4885MAOA 3306/4885 |
| US-20020016323-A1 | Oxazolidinone antibacterial agents having a thiocarbonyl functionality | OXA1L, MRPL21, TOP1 | F10 3383/4885MAOB 2998/4885MAOA 3306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.